Transversus Abdominis Plane (TAP) Block for Post Caesarian Pain (TAPBlock)

New York Presbyterian Brooklyn Methodist Hospital

Status and phase: Withdrawn; Phase 3

Conditions: Obstetrical Complications From Sedation During Parturition

Treatments: Drug: Bupivicaine

Study type: Interventional

Funder types: Other

Identifiers

NCT01986049

IRBNet # 367320

Details and patient eligibility

About

Adding TAP block with Bupivacaine may decrease the use of PCA bolus use after caesarean section for pain relief.

Full description

Participants in the study will be randomized to TAP block with 0.5% or 0.25% bupivacaine or with placebo (normal saline).

The number of PCA bolus used within 24 hours post cesarean section will be compared between the groups.

Sex: Female

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Healthy pregnant (ASA II) patients presenting for planned Cesarean delivery at New York Methodist Hospital under combined spinal epidural anesthesia

Exclusion criteria

• They are unable or are unwilling to take part in the study
• They have a history of allergy to any of the medications to be used in the study
• They have a history of drug abuse or chronic pain or opioid use
• They weigh less than 60kg
• They have a multiple gestation, placental disease, preeclampsia other disease of pregnancy
• They have a contraindication to neuraxial anesthesia (i.e., bleeding problems, bacteremia, etc.)
• They are unable to understand instructions or questions related to the study
• ASA III or IV

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

0 participants in 3 patient groups, including a placebo group

Bupivicaine 0.5%

Experimental group

Description:

Drug Bupivacaine 0.5%

Treatment:

Drug: Bupivicaine

Bupivicaine 0.25%

Experimental group

Description:

Drug Bupivacaine 0.25%

Treatment:

Drug: Bupivicaine

Normal Saline

Placebo Comparator group

Description:

Saline Normal

Treatment:

Drug: Bupivicaine